Category: Latest News
CMAC Statement on Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) accelerated review
The review of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), expected in Autumn 2025, has been brought forward and is due to conclude at the end of June 2025.
The Charities Medicines Access Coalition (CMAC), a coalition of 26 health charities (including SmellTaste) representing millions of patients across the UK, is calling for the Government and the pharmaceutical industry to be more transparent and share clear evidence that patient impact is at the heart of the ongoing VPAG discussions and negotiations.
- The Government must ensure all options being discussed for reform within the VPAG scheme are formally assessed for their impact on NHS patients.
- The Government and the pharmaceutical industry must also increase their communication and open meaningful discussions with patient organisations within this review.
This statement is supported by the following CMAC members: Action Bladder, Action for Pulmonary Fibrosis, Alzheimer’s Research UK, Breast Cancer Now, Blood Cancer Alliance, The Brain Tumour Charity, Brain Tumour Research, Cancer Research UK, Cancer 52, Cardiomyopathy UK, Cystic Fibrosis Trust, Diabetes UK, Genetic Alliance UK, JDRF UK, Kidney Research UK, Leukaemia UK, Make 2nds count, METUP UK, MNDA Association, MS Society, Myeloma UK, Neurological Alliance, Prostate Cancer UK, Retina UK, SmellTaste, Spinal Muscular Atrophy UK.
Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) accelerated review – Charity Statement
The Charities Medicines Access Coalition (CMAC), a coalition of 26 health charities representing millions of patients across the UK, is calling for the Government and the pharmaceutical industry to be more transparent and share clear evidence that patient impact is at the heart of the ongoing VPAG discussions and negotiations.
The review of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG), expected in Autumn 2025, has been brought forward and is due to conclude at the end of June 2025.
During the last round of negotiations, CMAC was clear that there must be meaningful engagement with patients and the groups that represent them, transparency around the process, and a joined-up approach to consult with stakeholders on patient-focused topics, including access, uptake, and outcomes. These negotiations and subsequent decisions will have a tangible impact on outcomes for the patient communities we work with.
Neither CMAC nor any of the individual patient organisations we represent have been consulted during this review process. This exclusion of patient voices only deepens our concern that patient benefit and access to effective treatments are not being treated as priorities in the Government’s negotiations with the pharmaceutical industry.
There is also a lack of transparency as to which elements of the VPAG scheme are being considered for amendment within this early review. This makes it challenging to understand or assess the impact that proposed revisions to the scheme may have on patients.
Whilst we would not expect to be involved in the confidential financial negotiations between the Government and the pharmaceutical industry, as patient representatives, we should be included in discussions around how VPAG funds are used to improve patient outcomes in the UK.
We are calling on the Government to ensure all options being discussed for reform within the VPAG scheme are formally assessed for their impact on NHS patients. We also call on the Government and the pharmaceutical industry to increase their communication and open meaningful discussions with patient organisations within this review.
Future work on the VPAG scheme, or any other proposal for reform of the UK’s treatment access systems and processes, must be fully inclusive of the patient voice and ultimately lead to faster, equitable access to new, innovative medicines.
Marking Anosmia Awareness Day 2025
Celebrating its 14th year in 2025, Thursday 27 February is Anosmia Awareness Day.
A mainstay on the SmellTaste calendar, this annual event serves as a catalyst for raising awareness about smell and taste disorders, an area in which SmellTaste is making significant progress, but there is still much work to be done.
For 2025, SmellTaste’s Anosmia Awareness Day social media campaign focuses on some of the main issues around smell dysfunction. These are:
- Anosmia, both congenital and acquired, and other smell and taste disorders are widely under-recognised
- Smell loss can be an early indicator of serious conditions
- Mental health can be seriously impacted by smell disorders
- A high number of people with a traumatic brain injury experience smell loss
- People with impaired smell can take simple and often free measures to stay safe at home
For SmellTaste, last year’s Anosmia Awareness Day was the biggest yet, with several partners getting on board and posting on social media to drive the conversation further.
This year we hope even more people will be inspired to support us to increase our reach, raising awareness of these under-recognised conditions and spreading the word that SmellTaste supports and represents anyone affected by a smell or taste disorder.
Please keep an eye on our social media channels on Thursday 27 February and engage with any content using the hashtag #AnosmiaAwarenessDay
The more people who support our campaign with a simple post, like, comment or share on social media, the further our vital messages will be amplified and the more we can push to get smell and taste dysfunction the recognition it needs.
Join us on Wednesday 26 February for the inaugural BeCOH webinar
SmellTaste is a founding member of the Breakthrough Consortium for Olfactory Health (BeCOH), which aims to advance the prevention, detection, and treatment of olfactory dysfunction. Register here for their introductory webinar on Wednesday 26 February. Don’t worry if you can’t attend. The webinar will be recorded and shared on our social media channels and via email to our members.
Other ways to help SmellTaste
This year, we launched our most ambitious campaign yet to raise £50,000 through a range of community-led fundraising activities that do more than just raise funds. Find out how you can join in 50 Ways to Raise 50K here.
You can also support SmellTaste by becoming a volunteer. We have a range of roles available, some taking a just few minutes of your time each week. To find out more, visit our website or email sally.connick@fifthsense.org.uk
Do you or someone you know have problems with your sense of smell and/or taste?
If you would like support or information about anosmia and other smell and taste disorders, visit our website where you can find support and resources and information sheets and support videos.
We also host online and in-person support groups where you can talk to others who understand what you are going through, share tips and advice, and build connections in a supportive environment. Please join for free as a SmellTaste member for information on our events, as well as updates on our work and more.
If you would like further support or information, you can email us at info@fifthsense.org.uk
SmellTaste statement on PRP injections for olfactory loss following recent media coverage
There has been recent media coverage about the potential for Platelet Rich Plasma (PRP) injections as a new way of treating smell loss.
Platelet‐rich plasma (PRP) is derived from fresh whole blood containing a high concentration of platelets. The blood is taken from the individual receiving the treatment. The PRP is then injected into the individual’s olfactory cleft. PRP has been explored as a potential treatment for other conditions, including arthritis.
Several research studies have been published where people with different forms of olfactory dysfunction have received a number of PRP injections over the course of several months. Some of the people involved in the studies experienced improvements in their sense of smell, as measured by a clinically validated smell test, whilst some experienced no improvement.
At this stage, PRP injections are an experimental treatment for olfactory dysfunction that has not been approved by NICE to treat NHS patients. The studies that have been undertaken so far show that PRP may offer potential benefit to some patients affected by olfactory loss, but that more work is needed, including double-blind randomized controlled trials involving larger numbers of patients, to get a better understanding of what benefits PRP may offer, and to which patient groups.
The recent media coverage focuses on one individual who has received one injection of Platelet Rich Plasma (PRP) from an ENT Consultant in London. Typically a randomised control trial would involve dozens of patients, and would assess ability to smell before and after treatment. It is unclear in this case whether a smell test was undertaken before or after the injection in order to establish the magnitude of any perceived effect.
SmellTaste supports research into better understanding the causes of olfactory dysfunction and finding new treatments. We want to see new treatments made available to patients on the NHS as soon as possible, with these having been evaluated in clinical trials, the gold standard being double-blind randomized controlled trials.
Details of two published papers on PRP for olfactory loss:
Use of platelet-rich plasma for COVID-19–related olfactory loss: a randomized controlled trial
https://doi.org/10.1002/alr.23116 This was an initial study involving 35 people affected by post-Covid smell dysfunction, 26 of whom completed the study
Long-term Outcomes of PRP Injections for Post-viral Olfactory Loss: A Prospective Cohort Study